Close Menu

NEW YORK (GenomeWeb) – Oxford BioDynamics said today that its subsidiary, Oxford BioDynamics Pte, has signed an exclusive license agreement with Nova Satra Diagnostics Asia (NSDA) under which NSDA will be able to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia using Oxford's EpiSwitch technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.